摘要
Background It remains uncertain whether first-line treatment with upfront brain radiotherapy (RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is superior to EGFR-TKIs alone for EGFR-mutated non-small cell lung cancer with newly diagnosed brain metastases (BMs). Therefore, we performed a meta-analysis to address this issue.Methods We searched PubMed, Embase, Cochrane Library, and Web of Science databases for eligible studies published until February 28, 2023. The primary outcomes of interest were overall survival (OS) and intracranial progression-free survival (iPFS), reported as hazard ratios (HRs) and 95% confidence intervals (CIs).Results Twenty-four retrospective studies with 3184 patients were included. First- or second-generation EGFR-TKIs were used in each study. Upfront brain RT plus EGFR-TKIs significantly prolonged OS (HR = 0.75, 95% CI: 0.64-0.88) and iPFS (HR = 0.61, 95% CI: 0.52-0.72) compared to EGFR-TKIs alone. There were no significant differences in OS and iPFS benefits from the combination therapy between asymptomatic and symptomatic patients, patients with exon 19 and 21 mutations, patients with 1-3 and > 3 BMs, and males and females, respectively (HRs interaction, P > 0.05 for each subgroup comparison).Conclusions First-line treatment with upfront brain RT plus EGFR-TKIs is likely to be more effective than EGFR-TKIs alone. The benefits of combination therapy did not appear to be significantly affected by BM-related symptoms, EGFR mutation subtype, number of BMs, or sex.
学科与关键词
- Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 StudyHou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Chen, Jing; Zhang, Baishen; You, Zhixuan; Liu, Qing; Chen, Likun*JAMA Network Open, 2023, 6(2): e2255050.被引 4
- EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
- Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancerPeng, Kai-Cheng; Su, Jun-Wei; Xie, Zhi; Wang, Han-Min; Fang, Mei-Mei; Li, Wen-Feng; Chen, Yu-Qing; Guan, Xu-Hui; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Tu, Hai-Yan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji*Thoracic Cancer, 2022, 13(11): 1619-1630.被引 5
